REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue5,872,2274,860,4274,103,728
Cost of Revenue397,061299,694392,709
Gross Profit5,475,1664,560,7333,711,019
Operating Expenses
Research Development2,075,1422,052,2951,620,577
Selling General and Administrative1,320,4331,177,697838,526
Non Recurring---
Total Operating Expenses---
Operating Income or Loss2,079,5911,330,7411,251,916
Income from Continuing Operations
Total Other Income/Expenses Net24,0396,269-12,578
Earnings Before Interest and Taxes2,103,6301,337,0101,239,338
Interest Expense25,1197,19514,241
Income Before Tax2,078,5111,329,8151,225,097
Income Tax Expense880,000434,293589,041
Minority Interest---
Net Income From Continuing Ops1,198,511895,522636,056
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income1,198,511895,522636,056
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares1,198,511895,522636,056